Metastatic triple-negative breast cancer (mTNBC), is the most severe and difficult type of breast cancer. This is a relatively unknown disease that affects approximately 5,000 young Spanish women every year. There is no cure for mTNCC, and only 12% survive five years. This data shows how critical it is to improve patients’ survival rates and quality of their lives. The biopharmaceutical company Gilead Sciences was faced with the challenge of raising awareness and making visible a disease that has largely gone untreated. They created the first “Coalition of Experts” to address the needs of metastatic triple-negative breast cancer patients.
Maria Rio, vice president of Gilead and general director, participated in the presentation. This initiative is led by more 20 women and thought leaders in their respective fields such as science, politics, or associative movement. They have examined the objective to address and make visible the challenges this type of cancer poses during the care and personal journeys of patients.
Despite advancements in other types of tumors, mTNCC has not seen much progress in the last few years. Women with this type of tumor face poor prognosis and have only had limited effective treatment options. This subtype of cancer has chemotherapy as the main treatment option. However, it is not likely to survive and does not respond well.
Pilar Fernandez of the Metastatic Breast Cancer Association insists that it is important to know what is going on because there are no issues that aren’t being discussed. Many women with metastatic triple-negative breast cancer are in a difficult situation. There are few options for treatment and they have a short life expectancy. We believe there must be a huge social movement to raise awareness about the current situation and make the new innovations available to everyone.
The Coalition also stressed the importance of raising awareness about the need for support measures for women with this type of cancer. It also encouraged research to improve the treatment of this disease, particularly for those who have a poor prognosis such as locally advanced tumors or metastasis to other parts of their bodies.
They are the ones who give voice to more than 5,000 women with metastatic triple-negative breast cancer.
* Monica Alminana, Undersecretary of Ministry of Universal Health and Public Health of Eva Generalitat Valenciana
* Cristina Avendano, Head of the Clinical Pharmacology Service at Hospital Puerta de Hierro
* Ines Ballester, Journalist and Television Presenter.
* Candela Cale: General Director of the Sant Francesc d’Assis Foundation. Member of the SEDISA Board of Directors.
* Esther Carmona, Health spokesperson for the Socialist Group at the Senate
* Eva Carrasco is a medical oncologist. Scientific Director and CEO at GEICAM (Spanish Breast Cancer Research Group).
* Eva Ciruelos, medical oncologist at Hospital Universitario 12 de Octubre (Madrid)
* Olga Delgado, President of the SEFH, Head of the Hospital Pharmacy Service at Son Espases University Hospital.
* Tania Estape: clinical psychologist. President of the Spanish Society of Psychooncology.
* Pilar Fernandez, patient and president of Association of Metastatic Breast Cancer Patients.
* Marta de la Fuente, head of the MD Anderson Cancer Center Madrid Psycho-oncology Service.
* Gema Gonzalez, Vice President of Spanish Society of Oncology Nursing.
* Trinidad Jimenez: former Minister of Health.
* Coral Larrosa is a journalist. Telecinco news, Society section. Specialized in Science and Health.
* Laura Lema is an oncologist at 12 de Octubre University Hospital Medical Oncology Service.
* Rosario Lopez: PhD in Mathematics. Professor at the Faculty of Medicine of UAM. Expert in Health and Gender. Membre of the University Institute for Women’s Studies of the UAM.
* Irene Mangues, pharmacist at the Arnau University Hospital Vilanova de Lleida
* Estela Moreno: pharmacist at Santa Creu i Sant Pau University Hospital BCN. GEDEFO coordinator.
* Gema Moreno Bueno: Coordinator of ASEICA Women. Professor at the Faculty of Medicine-UAM in the Department of Biochemistry. Director of the Research Laboratory at the MD Anderson Foundation.
* Eloina Nunez, managing director at Complejo Hospitalario Universitario Santiago de Compostela
* Mafalda oliveira: Medical Oncologist. Medical Oncology Service at the Vall d’Hebron University Hospital.
Ana Pastor: doctor. 2nd Vice President of Congress. Former Minister of Health.
* Rosa Romero, President of the Health Commission at the Congress of Deputies.
* Marta Santisteban, medical oncologist at Navarra University Clinic
* Elvira Velasco, spokesperson for Health in Health and Consumption Commission of Congress of Deputies.
The ‘Manifesto to the visibility of the needs of women living with CMTNm’ will collect the results of the meetings of the ‘Coalition of Experts. It will address the need for access to treatment and therapies, improved diagnosis, comprehensive monitoring of patients from multiple disciplines, or care that is based on excellence.
This document will be presented at a Public Seminar within the World Metastatic Breast Cancer Day framework on October 13. That date is when any individual or entity can sign the Manifesto to support breast cancer patients. triple negative metastatic breast.
